Suppr超能文献

成人终末期肾病中伴SMARCB1(INI1)失活的Xp11.2易位性肾细胞癌:一例报告

An Xp11.2 translocation renal cell carcinoma with SMARCB1 (INI1) inactivation in adult end-stage renal disease: a case report.

作者信息

Yu Lu, Li Jun, Xu Sanpeng, Navia Miranda Mariajose, Wang Guoping, Duan Yaqi

机构信息

Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China.

Department of Pathology, School of Basic Medical Science, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China.

出版信息

Diagn Pathol. 2016 Oct 12;11(1):98. doi: 10.1186/s13000-016-0551-x.

Abstract

BACKGROUND

Xp11.2 translocation/transcription factor E3 (TFE3) rearrangement renal cell carcinoma (RCC) is a rare subtype of RCC with limited clinical and pathological data.

CASE PRESENTATION

Here we present an unusual high-grade Xp11.2 translocation RCC with a rhabdoid feature and SMARCB1 (INI1) inactivation in a 40-year-old man with end-stage kidney disease. The histological examination of the dissected left renal tumor showed an organoid architecture of the eosinophilic or clear neoplastic cells with necrosis and high mitotic activity. In some areas, non-adhesive tumor cells with eccentric nuclei were observed. Immunohistochemically (IHC), the tumor cells are positive for TFE3 and the renal tubular markers (PAX2 and PAX8), and completely negative for SMARCB1, an oncosuppressor protein. Break-apart florescence in situ hybridization and reverse transcription polymerase chain reaction confirmed TFE3 rearrangement on Xp11.2 and the presence of ASPSCR1-TFE3 fusion gene. DNA sequencing revealed a frameshift mutation in exon 4 of SMARCB1 gene.

CONCLUSION

It is important to recognize this rare RCC with both TFE3 rearrangement and SMARCB1 inactivation, as the prognosis and therapeutic strategies, particularly targeted therapies for such tumors, might be different.

摘要

背景

Xp11.2易位/转录因子E3(TFE3)重排性肾细胞癌(RCC)是RCC的一种罕见亚型,临床和病理数据有限。

病例报告

在此,我们报告一例罕见的高级别Xp11.2易位性RCC,具有横纹肌样特征且SMARCB1(INI1)失活,患者为一名40岁患有终末期肾病的男性。对切除的左肾肿瘤进行组织学检查,显示嗜酸性或透明肿瘤细胞呈器官样结构,伴有坏死和高有丝分裂活性。在某些区域,观察到具有偏心核的非粘附性肿瘤细胞。免疫组织化学(IHC)检测显示,肿瘤细胞TFE3及肾小管标志物(PAX2和PAX8)呈阳性,而抑癌蛋白SMARCB1呈完全阴性。断裂荧光原位杂交和逆转录聚合酶链反应证实了Xp11.2上的TFE3重排以及ASPSCR1-TFE3融合基因的存在。DNA测序显示SMARCB1基因第4外显子存在移码突变。

结论

认识到这种同时具有TFE3重排和SMARCB1失活的罕见RCC很重要,因为其预后和治疗策略,尤其是针对此类肿瘤的靶向治疗可能会有所不同。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59a0/5062893/28a1a11e5c21/13000_2016_551_Fig1_HTML.jpg

相似文献

4
Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
Am J Surg Pathol. 2013 Aug;37(8):1150-63. doi: 10.1097/PAS.0b013e31828a69ae.
8
TMED6-COG8 is a novel molecular marker of TFE3 translocation renal cell carcinoma.
Int J Clin Exp Pathol. 2015 Mar 1;8(3):2690-9. eCollection 2015.

引用本文的文献

1
The WHO 2022 Classification of Renal Neoplasms (5th Edition): Salient Updates.
Cureus. 2024 Apr 17;16(4):e58470. doi: 10.7759/cureus.58470. eCollection 2024 Apr.
2
Update on Selected High-grade Renal Cell Carcinomas of the Kidney: FH-deficient, ALK-rearranged, and Medullary Carcinomas.
Adv Anat Pathol. 2024 Mar 1;31(2):118-125. doi: 10.1097/PAP.0000000000000426. Epub 2023 Dec 25.

本文引用的文献

2
Epithelioid malignant peripheral nerve sheath tumor: clinicopathologic analysis of 63 cases.
Am J Surg Pathol. 2015 May;39(5):673-82. doi: 10.1097/PAS.0000000000000379.
5
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia.
Am J Surg Pathol. 2013 Oct;37(10):1469-89. doi: 10.1097/PAS.0b013e318299f2d1.
6
SMARCB1/INI1 inactivation in renal medullary carcinoma.
Histopathology. 2012 Sep;61(3):428-35. doi: 10.1111/j.1365-2559.2012.04228.x. Epub 2012 Jun 11.
7
Molecular heterogeneity of TFE3 activation in renal cell carcinomas.
Mod Pathol. 2012 Feb;25(2):308-15. doi: 10.1038/modpathol.2011.169. Epub 2011 Oct 28.
8
Immunohistochemical analysis of SMARCB1/INI-1 expression in collecting duct carcinoma.
Urology. 2011 Aug;78(2):474.e1-5. doi: 10.1016/j.urology.2011.04.043. Epub 2011 Jun 25.
9
A novel case of rhabdoid colon carcinoma associated with a positive CpG island methylator phenotype and BRAF mutation.
Hum Pathol. 2011 Jul;42(7):1047-52. doi: 10.1016/j.humpath.2010.10.016. Epub 2011 Feb 11.
10
Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.
Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):319-24. doi: 10.1073/pnas.0913297108. Epub 2010 Dec 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验